NantKwest (NASDAQ:NK) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, April 10th.
A number of other equities research analysts have also weighed in on NK. Raymond James Financial reissued a “hold” rating on shares of NantKwest in a report on Monday, December 11th. Zacks Investment Research lowered shares of NantKwest from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Three research analysts have rated the stock with a sell rating and three have given a hold rating to the company’s stock. NantKwest currently has an average rating of “Hold” and a consensus price target of $4.00.
Shares of NantKwest stock traded up $0.19 during trading hours on Tuesday, hitting $4.20. The company’s stock had a trading volume of 157,329 shares, compared to its average volume of 237,973. NantKwest has a 1-year low of $2.71 and a 1-year high of $8.45. The firm has a market capitalization of $301.11, a P/E ratio of -3.34 and a beta of 2.83. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.01.
ILLEGAL ACTIVITY WARNING: “NantKwest (NASDAQ:NK) Cut to “Strong Sell” at BidaskClub” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://weekherald.com/2018/04/17/nantkwest-nk-downgraded-by-bidaskclub.html.
NantKwest Company Profile
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.